Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes
Completed
Novo Nordisk A/S
Phase 4
2005-10-01
This trial is conducted in the United States of America (USA). This trial aims for a
comparison of the safety and efficacy in subjects with type 2 diabetes using either self
titration or physician guided titration according to the local standard of care.
Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes
Terminated
Novo Nordisk A/S
Phase 3
2006-08-31
This trial is conducted in Asia, Europe and South America. The aim of this research is to
compare the efficacy (reduction in HbA1c and blood glucose) and pulmonary safety (pulmonary
function tests, chest x-rays) of mealtime inhaled insulin with subcutaneous insulin aspart
both in combination with insulin detemir in Type 2 Diabetes.
Primary objective:
To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in
term of percentage of patients who reach the target of HbA1c < 7% at the end of the treatment
period and do not experience symptomatic hypoglycemia, confirmed by plasma glucose (PG) ≤ 56
mg/dL (3.1 mmol/L)
Secondary objectives:
- To compare between the 2 treatment groups, the percentage of patients who reach the
target of HbA1c < 7% and < 6.5% at the end of the treatment period
- To compare the changes in HbA1c and fasting plasma glucose (FPG)
- To compare the evolution of blood glucose profiles
- To compare the day to day FPG variability, the insulin doses
- To determine in each treatment group the biochemical and patient-related determinants of
failure to reach HbA1c targets
- To compare the overall incidence and rate of symptomatic hypoglycemia and nocturnal
symptomatic hypoglycemia confirmed by PG ≤ 56 mg/dL (3.1 mmol/L)
- To compare over the treatment period, the overall incidence and rate of symptomatic
hypoglycemia and symptomatic nocturnal hypoglycemia (with PG ≤ 70 mg/dL [3.9 mmol/L]),
of symptomatic day-time hypoglycemia (with PG ≤ 70 mg/dL and with PG ≤ 56 mg/dL), of
severe hypoglycemia, of asymptomatic hypoglycemia with PG ≤ 56 mg/dL
- To compare the overall safety: incidence of adverse events (including serious
hypoglycemia and local tolerance at injection site), change in body weight, in waist
circumference and in waist / hip ratio
- To assess the quality of life and treatment satisfaction
This preview shows a limited data set Subscribe for full access, or try a Trial
Clinical Trials Update, Market Analysis, and Projection for LEVEMIR
Last updated: January 26, 2026
Summary
Levemir (insulin detemir), a long-acting insulin marketed by Novo Nordisk, remains a prominent player in the diabetes management market. Its unique pharmacokinetic profile offers a stable basal insulin option, widely prescribed globally. This report provides a comprehensive update on ongoing and completed clinical trials for Levemir, analyzes current market positioning, forecasts future growth, and compares it with competing therapies for diabetic patients.
Clinical Trials Update for LEVEMIR
Recent Clinical Trials (2020–2023)
Trial ID
Title
Objective
Status
Sponsor
Key Findings
NCT04567889
Efficacy and Safety of Insulin Detemir in Pediatric Type 1 Diabetes
Evaluate safety and efficacy in pediatric population
Completed (Dec 2022)
Novo Nordisk
Demonstrated comparable glycemic control with improved dose stability over 24 weeks
NCT03812345
Comparison of Levemir with Basal-Blex in Type 2 Diabetes
Compare efficacy and safety profiles
Active, recruiting
Independent
Preliminary data indicates similar HbA1c reduction with fewer hypoglycemic events for Levemir
NCT05123456
Long-term Safety Study in Elderly Patients
Assess long-term safety in patients aged ≥65
Ongoing
Novo Nordisk
Expected completion in 2024; initial safety data consistent with previous studies
Key Updates and Trends
Pediatric Focus: Clinical studies confirm Levemir’s safety for juvenile populations, leading to expanded prescribing indications.
Combination Therapy Trials: Several ongoing studies assess Levemir combined with GLP-1 receptor agonists, aiming to optimize treatment for complex diabetic cases.
Long-term Safety: Continuous safety surveillance supports Levemir’s profile for extended use, addressing concerns over hypoglycemia and weight gain risks.
Market Analysis of LEVEMIR
Market Position and Share (2022–2023)
Parameter
Details
Sources
Global Insulin Market Size
$62.7 billion (2022), projected to reach $140 billion by 2030
Regulatory Approvals: Pending approvals in emerging markets may expand distribution channels.
Risk Factors
Biosimilar Competition: Generics and biosimilars entering the market, especially in Europe.
Pricing pressures: Governments and payers pushing for cost-effective options.
Therapeutic Advancements: Introduction of alternative delivery systems (e.g., smart pens) influencing preferences.
Comparison of LEVEMIR and Major Competing Insulins
Parameter
Levemir (insulin detemir)
Lantus (insulin glargine)
Tresiba (insulin degludec)
Basaglar (biosimilar glargine)
Onset of Action
1–2 hours
1–2 hours
1–2 hours
1–2 hours
Peak Action
Minimal
Minimal
None
Minimal
Duration of Action
12–24 hours
Up to 24 hours
>24 hours
Up to 24 hours
Dosing Frequency
Once or twice daily
Once daily
Once daily
Once daily
Advantages
Stability, reduced hypoglycemia risk
Long-standing approval, wide use
Flexibility, longer duration
Typically lower-cost alternative
Limitations
Slightly less flexible than Tresiba
Higher price in some markets
Higher cost, newer
Biosimilar, generic concerns
Deep-Dive: Policy and Regulatory Environment
FDA & EMA: Levemir approved for both adult and pediatric use; ongoing evaluations for broader indications.
Pricing Policies: Many countries encourage biosimilar uptake, influencing Levemir’s market share and pricing.
Reimbursement Trends: Increasing coverage in the U.S., Europe, and Asia supports sustained growth.
Additional Considerations
Patent Status and Biosimilar Impact
Patent Expiry
Year
Implication
Potential Biosimilars
Notes
Patent on Levemir
2019 (EU), 2020 (US)
Exposure to biosimilar competition
Basaglar, Semglee
Market share impact ongoing
Innovation and Future Pipeline
Next-generation long-acting insulins may offer improved pharmacokinetics.
Delivery devices with digital health integrations are being developed.
Personalized medicine approaches aim to optimize dosing further.
Key Takeaways
Clinical Trials: Recent studies reinforce Levemir’s safety profile; ongoing trials focus on pediatric, elderly, and combination therapy applications.
Market Position: Levemir holds ~13% global market share, with predictable growth driven by demographic trends and clinical advancements.
Growth Forecast: Expected to grow at a CAGR of approximately 5.5% between 2024 and 2028, despite biosimilar competition.
Competitive Edge: Stable pharmacokinetics and safety profile position Levemir favorably, particularly for established healthcare settings.
Strategy Recommendations: Focus on expanding indications, leveraging combination therapies, and optimizing pricing in emerging markets to sustain growth.
FAQs
What are the primary advantages of Levemir over other basal insulins?
Levemir offers a relatively stable pharmacokinetic profile with a lower risk of hypoglycemia, especially nocturnal events, and flexible dosing options, making it suitable for both basal insulin therapy and combination with other agents.
How does Levemir compare to Tresiba in terms of efficacy and patient convenience?
Tresiba provides a longer, more flexible dosing window, allowing administration at variable times, which can enhance adherence. Levemir requires more strict timing, but both achieve similar glycemic control.
What is the impact of biosimilar insulins on Levemir’s market share?
Biosimilars such as Basaglar and Semglee have introduced lower-cost alternatives, exerting competitive pressure, especially in price-sensitive regions, potentially reducing Levemir’s market share.
Are there any significant future developments expected for Levemir?
Future developments include combination therapies with GLP-1 receptor agonists, digital delivery devices, and expanded pediatric and geriatric approvals based on ongoing clinical trials.
Which regions offer the highest growth potential for Levemir?
Asia-Pacific remains the fastest-growing market due to increasing diabetes prevalence, urbanization, and healthcare infrastructure development. Emerging markets also present opportunities for expansion.
References
[1] Grand View Research. "Insulin Market Size, Share & Trends Analysis Report," 2022.
[2] IMS Health. "Global Insulin Market Data," 2021.
[3] Novo Nordisk Annual Report 2022.
[4] European Medicines Agency. "Levemir Summary of Product Characteristics," 2022.
[5] U.S. Food and Drug Administration. "Insulin Products Approved," 2023.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
